Claims for Patent: 6,555,381

Summary for Patent: 6,555,381

Title:	Method for determining a contact activator for platelet activation
Abstract:	A method of determining a contact activator for platelet activation and/or clotting activation is provided, comprising placing a predetermined amount of an anticoagulant in each cell of a multicell test cartridge, placing a predetermined amount of a platelet inactivating agent in each cell, and placing a measured amount of contact activator in each cell, the amount of contact activator in each cell differing from the amount in each other cell. An aliquot of a blood sample is added to each cell, and the blood sample aliquot, clotting reagent and platelet inactivating agent are mixed. Each cell sample is allowed to clot, and the clotting time for each cell is measured. The relative clotting times are used to determine the platelet activation and/or clotting activation effect of the clotting activator.
Inventor(s):	Baugh; Robert F. (Parker, CO), Lane; Carole G. (Greenwood Village, CO), Wilson; Adrian C. (Denver, CO)
Assignee:	Medtronic, Inc. (Minneapolis, MN)
Application Number:	09/810,740
Patent Claims:	1. A method for determining a contact activator for platelet activation and/or clotting activation using a coagulation detection apparatus, said apparatus comprising a first, a second and a third test cell, each of said cells comprising an anticoagulant and a platelet inactivating agent wherein said first cell further comprises a first contact activator, said second cell further comprises a second contact activator and said third cell does not contain a contact activator, said method comprising: a) dividing the sample of blood into first, second and third partial samples; b) dispensing the first partial sample into the first test cell to form a first test mixture; c) performing a first activated clotting time test on the first test mixture to obtain a first clotting time; d) repeating the aforementioned steps of dispensing and performing an activated clotting time test on each of said second and third partial samples to obtain a second and third clotting time; and e) comparing the activated clotting times of the first, second, and third partial samples to determine whether the contact activator functions to mechanically activate platelets and/or clotting. 2. The method of claim 1, wherein said first and second contact activators comprise particles having negatively charged surfaces. 3. The method of claim 1, wherein the comparing step further comprises preparing a titration curve by plotting the activated clotting times of the first, second, and third partial samples. 4. The method of claim 1, wherein said anticoagulant is heparin. 5. The method of claim 4, wherein the amount of heparin in each cell is between about 1 unit and about 4 units per milliliter of blood sample. 6. The method of claim 1, wherein said platelet inactivating agent is selected from the group consisting of Abciximab, 4-[4-[4-(aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidineacetic acid, hydrochloride trihydrate, and acetylsalicylic acid. 7. The method of claim 2, wherein one of said contact activators is kaolin. 8. The method of claim 2, wherein one of said contact activators is diatomaceous earth. 9. The method of claim 2, wherein one of said contact activators is powdered glass. 10. The method of claim 2, wherein one of said contact activators is silica. 11. A method of determining a dose response for a contact activator for platelet activation and/or clotting activation, said method comprising: a) placing a predetermined amount of anticoagulant in each cell of a multicell test cartridge; b) placing predetermined amount of a platelet inactivating agent in each said cell; c) placing a measured amount of said contact activator in each said cell, the amount of said contact activator in each cell differing from the amount in each other cell; d) adding an aliquot of a blood sample to each said cell, mixing said blood sample aliquot, contact activator and platelet inactivating agent; e) clotting each cell sample and measuring the clotting time for each said cell; and f) computing the relative clotting times to determine the platelet activation and/or clotting activation effect of the contact activator. 12. The method of claim 11, wherein said anticoagulant is heparin. 13. The method of claim 12, wherein the amount of heparin in each cell is between about 1 unit and about 4 units per milliliter of blood sample. 14. The method of claim 11, wherein the contact activator comprises particles having negatively charged particles. 15. The method of claim 14, wherein said contact activator is kaolin. 16. The method of claim 14, wherein said contact activator is diatomaceous earth. 17. The method of claim 14, wherein said contact activator is powdered glass. 18. The method of claim 14, wherein said contact activator is silica. 19. The method of claim 11, wherein said platelet inactivating agent is selected from the group consisting of Abciximab, 4-[4-[4-(aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidineacetic acid, hydrochloride trihydrate, and acetylsalicylic acid.

Details for Patent 6,555,381

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2016-04-30